.png)
The Founder's Story
Jeffrey Carlisle is also the founder of Fluidnet (Ivenix), which sold to Fresenius in 2022. He holds many patents for infusion therapy products, starting in 1978. Jeffrey began his career by leading the development of groundbreaking designs in cardiography and peritoneal dialysis. He also launched Bard Electrophysiology, which sold to Boston Scientific.
A winning team collaborating to
transform infusion care
Success at prominent medical device and analytics companies
Hewlett-Packard; American Hospital Supply; FluidSense; Ivenix; IVAC; Home Healthcare of America; CORAM; Alaris; BD; Delphi; Harvard Apparatus; CR Bard; Medex; Smiths Medical; Koru; DEKA; IVAC; IMED; Baxter; OptionCare;Minimed; Live Ramp
Experts across all critical disciplines
Engineering: systems, mechanical, industrial, electronics, embedded, reliability, database, UX; Manufacturing; Operations, Finance; Regulatory; IP; Marketing; Clinical: RN, Pharm; Data analytics; Sc.B, MS, PhD, MBA, JD, RPh, FASHP, FNHIA
World Class Partners
We have partnered with well established leaders in advanced manufacturing, distribution, web services, and global R&D leaders. This lets our small team focus on inventing and lean on the experiences of others. We know where to go to get the job done and done right.
